Peptide delivery to the CNS: Bypassing the Blood-brain Barrier
Michael Hite
CEO, Impel NeuroPharma
Impel NeuroPharma has developed an intranasal delivery device that allows for direct access to the brain through bypassing the blood-brain barrier, which limits the transport of drugs from circulating blood to the CNS (Central Nervous System). The Company enables the delivery of large molecule therapeutics that have the potential to drastically revolutionize CNS disease treatment plans, and improves the delivery of small molecules to lower systemic drug exposure and reduce patient side effects compared to existing therapies. Impel NeuroPharma’s technology platform opens up the ~99% of peptides that can’t reach the brain when administered systemically due to plasma instability or lack of BBB access, with the potential to drastically improve the treatment of brain-related diseases and conditions for patients worldwide.